Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Themis Medicare Limited ( (IN:THEMISMED) ) has issued an announcement.
Themis Medicare has issued a corrigendum to its February 25, 2026 postal ballot notice seeking shareholder approval for a preferential issue of convertible equity warrants to promoter group entity Vividhmargi Investments. Following observations from the National Stock Exchange during in-principle approval review, the company has revised key terms, including increasing the warrant issue price from Rs 100 to Rs 102.87 per warrant, which raises the aggregate issue size to about Rs 47.28 crore.
The corrigendum, which modifies specific wording and financial details in the original resolution and explanatory statement, will be circulated electronically to members and published in English and Gujarati newspapers, as well as uploaded on the BSE, NSE and company websites to ensure adequate disclosure ahead of e-voting. The move underscores regulatory-driven fine-tuning of the capital-raising proposal and signals continued efforts by the promoter group to infuse equity-linked capital into the company via a preferential route.
More about Themis Medicare Limited
Themis Medicare Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of formulations and active pharmaceutical ingredients. The company focuses on branded and generic medicines, serving domestic and international markets from its facilities in Gujarat and its corporate office in Mumbai.
Average Trading Volume: 8,542
Technical Sentiment Signal: Sell
Current Market Cap: 7.05B INR
For detailed information about THEMISMED stock, go to TipRanks’ Stock Analysis page.